{"result": {"id": "930f8273-730c-4cd2-ad7a-bd982aa5ab37", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "(\"entity\"<|>韦和泰利霉素<|>PERSON<|>韦和泰利霉素是一种药物，与沙格列汀合用时能显著升高沙格列汀的血药浓度)\n##\n(\"entity\"<|>卡马西平<|>PERSON<|>卡马西平是一种CYP3A4/5诱导剂，与沙格列汀合用时能加快沙格列汀的代谢)\n##\n(\"entity\"<|>地高辛<|>PERSON<|>地高辛是一种药物，与西格列汀合用时可能升高其Cmax)\n##\n(\"entity\"<|>环孢素<|>PERSON<|>环孢素是一种P-gp抑制剂，与阿格列汀合用不存在临床意义的相互作用)\n##\n(\"entity\"<|>利福平<|>PERSON<|>利福平是一种P-gp诱导剂，与利格列汀和维格列汀合用时可能降低其疗效)\n##\n(\"entity\"<|>吉非罗齐<|>PERSON<|>吉非罗齐是一种CYP2C8抑制剂，能减慢罗格列酮和吡格列酮的代谢)\n##\n(\"entity\"<|>氯吡格雷<|>PERSON<|>氯吡格雷是一种CYP2C8抑制剂，能减慢罗格列酮和吡格列酮的代谢)\n##\n(\"entity\"<|>硝苯地平<|>PERSON<|>硝苯地平是一种CCB类药物，主要经CYP3A4代谢)\n##\n(\"entity\"<|>非洛地平<|>PERSON<|>非洛地平是一种CCB类药物，主要经CYP3A4代谢)\n##\n(\"entity\"<|>氨氯地平<|>PERSON<|>氨氯地平是一种CCB类药物，主要经CYP3A4代谢)\n##\n(\"entity\"<|>伊曲康唑<|>PERSON<|>伊曲康唑是一种CYP3A4强抑制剂，能减慢CCB类药物的代谢)\n##\n(\"entity\"<|>氟康唑<|>PERSON<|>氟康唑是一种CYP3A4强抑制剂，能减慢CCB类药物的代谢)\n##\n(\"entity\"<|>克拉霉素<|>PERSON<|>克拉霉素是一种CYP3A4强抑制剂，能减慢CCB类药物的代谢)\n##\n(\"relationship\"<|>沙格列汀<|>韦和泰利霉素<|>韦和泰利霉素能显著升高沙格列汀的血药浓度<|>8)\n##\n(\"relationship\"<|>沙格列汀<|>卡马西平<|>卡马西平能加快沙格列汀的代谢，降低其降糖活性<|>7)\n##\n(\"relationship\"<|>西格列汀<|>地高辛<|>西格列汀与地高辛合用时可能升高地高辛的Cmax<|>6)\n##\n(\"relationship\"<|>阿格列汀<|>环孢素<|>阿格列汀与环孢素合用不存在临床意义的相互作用<|>4)\n##\n(\"relationship\"<|>利格列汀<|>利福平<|>利福平可能降低利格列汀的疗效<|>6)\n##\n(\"relationship\"<|>维格列汀<|>利福平<|>利福平可能降低维格列汀的疗效<|>6)\n##\n(\"relationship\"<|>罗格列酮<|>吉非罗齐<|>吉非罗齐能减慢罗格列酮的代谢<|>7)\n##\n(\"relationship\"<|>吡格列酮<|>吉非罗齐<|>吉非罗齐能减慢吡格列酮的代谢<|>7)\n##\n(\"relationship\"<|>罗格列酮<|>氯吡格雷<|>氯吡格雷能减慢罗格列酮的代谢<|>7)\n##\n(\"relationship\"<|>吡格列酮<|>氯吡格雷<|>氯吡格雷能减慢吡格列酮的代谢<|>7)\n##\n(\"relationship\"<|>硝苯地平<|>CYP3A4<|>硝苯地平主要经CYP3A4代谢<|>8)\n##\n(\"relationship\"<|>非洛地平<|>CYP3A4<|>非洛地平主要经CYP3A4代谢<|>8)\n##\n(\"relationship\"<|>氨氯地平<|>CYP3A4<|>氨氯地平主要经CYP3A4代谢<|>8)\n##\n(\"relationship\"<|>硝苯地平<|>伊曲康唑<|>伊曲康唑能减慢硝苯地平的代谢<|>7)\n##\n(\"relationship\"<|>非洛地平<|>伊曲康唑<|>伊曲康唑能减慢非洛地平的代谢<|>7)\n##\n(\"relationship\"<|>氨氯地平<|>伊曲康唑<|>伊曲康唑能减慢氨氯地平的代谢<|>7)\n##\n(\"relationship\"<|>硝苯地平<|>氟康唑<|>氟康唑能减慢硝苯地平的代谢<|>7)\n##\n(\"relationship\"<|>非洛地平<|>氟康唑<|>氟康唑能减慢非洛地平的代谢<|>7)\n##\n(\"relationship\"<|>氨氯地平<|>氟康唑<|>氟康唑能减慢氨氯地平的代谢<|>7)\n##\n(\"relationship\"<|>硝苯地平<|>克拉霉素<|>克拉霉素能减慢硝苯地平的代谢<|>7)\n##\n(\"relationship\"<|>非洛地平<|>克拉霉素<|>克拉霉素能减慢非洛地平的代谢<|>7)\n##\n(\"relationship\"<|>氨氯地平<|>克拉霉素<|>克拉霉素能减慢氨氯地平的代谢<|>7)\n<|COMPLETE|>", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1752166544, "model": "deepseek-chat", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_8802369eaa_prod0623_fp8_kvcache", "usage": {"completion_tokens": 1333, "prompt_tokens": 3904, "total_tokens": 5237, "completion_tokens_details": null, "prompt_tokens_details": {"audio_tokens": null, "cached_tokens": 3840}, "prompt_cache_hit_tokens": 3840, "prompt_cache_miss_tokens": 64}}, "input": {"messages": [{"content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: 韦和泰利霉素）合用时，能显著升高 沙格列汀血药浓度，合用时沙格列汀的 日剂量不超过 2.5 mg。而沙格列汀与卡马西平（CYP3A4/5 诱导剂 ） 合用时，可通过加快沙格列汀的代谢，显著降低其降糖  活性［17］。\n　　西格列汀少量经 CYP3A4 和 CYP2C8 代谢，临床意 义的相互作用比较少见。西格列汀是 P-gp 的底物，与 地高辛合用可升高地高辛的 Cmax ，两者合用时需谨慎。  如果不能停用西格列汀，则需监测地高辛血药浓度［18］。\n　　阿格列汀、利格列汀和维格列汀在人体内基本不经 CYP450 酶代谢，不存在药物代谢酶相关的相互作用。 阿格列汀不是 P-gp 底物，与地高辛（P-gp 底物）、环 孢素（P-gp 抑制剂）合用不存在临床意义的相互作用。\n　　　利格列汀和维格列汀基本不通过CYP450 酶代谢，  但均是P-gp 的底物，与P-gp 诱导剂（如利福平）合用时， 会降低其疗效；维格列汀与血管紧张素转化酶抑制剂 （ACEI ）合用时，可能增加血管神经性水肿的风险［19-20］。 \t4.1.6    噻唑烷二酮类  罗格列酮、 吡格列酮主要经 CYP2C8 代谢。CYP2C8 抑制剂（ 如吉非罗齐、 氯吡格 雷）等能显著减慢此类药物的代谢，升高其血药浓度； CYP2C8 强诱导剂（如利福平）能加快药物代谢， 降低 疗效。\n4.1.7     钠 - 葡 萄 糖 共 转 运 蛋 白 2（SGLT-2 ）抑 制剂\n　　达格列净主要经UGT1A9 代谢为无活性的达格列净 3-O- 葡糖苷酸，仅有极少量经CYP450 酶代谢。\n　　恩格列净在体内经 UGT2B7 、UGT1A3 、UGT1A8 、 UGT1A9 代谢 为无 活 性 的 葡 糖 苷 酸，不 抑 制、诱 导 CYP450 酶，不抑制 UGT1A1，药物相互作用少见。\n　　卡格列净仅有 7% 经 CYP3A4 代谢，不诱导、抑制 CYP450 酶。\n　　降糖药相关药物相互作用的潜在危害及处置见 表 1。\n4.2    降压药\n4.2.1    钙离子拮抗剂（CCB ）  CCB 类药物（如硝苯地  平、非洛地平、氨氯地平等）主要经肝脏 CYP3A4 代谢， CYP3A4 强抑制剂（如伊曲康唑、氟康唑、克拉霉素等） 能够显著减慢这类药物的代谢，从而增强降压效果，可\n\n\n\n·3536 · http://www.chinagp.net   E-mail:zgqkyx@chinagp.net.cn\n表 1    降糖药相关药物相互作用的潜在危害及处置\nTable 1     Potential risk and management of drug interactions in the treatment of diabetes\n药物\n######################\nOutput:", "role": "user"}, {"role": "assistant", "content": "(\"entity\"<|>沙格列汀<|>PERSON<|>沙格列汀是一种药物，与韦和泰利霉素合用时血药浓度会升高，与卡马西平合用时降糖活性会降低)\n##\n(\"entity\"<|>西格列汀<|>PERSON<|>西格列汀是一种药物，少量经CYP3A4和CYP2C8代谢，是P-gp的底物，与地高辛合用时需谨慎)\n##\n(\"entity\"<|>阿格列汀<|>PERSON<|>阿格列汀是一种药物，基本不经CYP450酶代谢，不是P-gp底物，与地高辛和环孢素合用无临床意义的相互作用)\n##\n(\"entity\"<|>利格列汀<|>PERSON<|>利格列汀是一种药物，基本不经CYP450酶代谢，是P-gp的底物，与P-gp诱导剂合用时疗效会降低)\n##\n(\"entity\"<|>维格列汀<|>PERSON<|>维格列汀是一种药物，基本不经CYP450酶代谢，是P-gp的底物，与ACEI合用时可能增加血管神经性水肿的风险)\n##\n(\"entity\"<|>罗格列酮<|>PERSON<|>罗格列酮是一种药物，主要经CYP2C8代谢)\n##\n(\"entity\"<|>吡格列酮<|>PERSON<|>吡格列酮是一种药物，主要经CYP2C8代谢)\n##\n(\"entity\"<|>达格列净<|>PERSON<|>达格列净是一种药物，主要经UGT1A9代谢为无活性的达格列净3-O-葡糖苷酸)\n##\n(\"entity\"<|>恩格列净<|>PERSON<|>恩格列净是一种药物，经UGT2B7、UGT1A3、UGT1A8、UGT1A9代谢为无活性的葡糖苷酸)\n##\n(\"entity\"<|>卡格列净<|>PERSON<|>卡格列净是一种药物，仅有7%经CYP3A4代谢)\n##\n(\"entity\"<|>CYP3A4<|>ORGANIZATION<|>CYP3A4是一种代谢酶，参与多种药物的代谢)\n##\n(\"entity\"<|>CYP2C8<|>ORGANIZATION<|>CYP2C8是一种代谢酶，参与多种药物的代谢)\n##\n(\"entity\"<|>P-gp<|>ORGANIZATION<|>P-gp是一种转运蛋白，影响药物的吸收和分布)\n##\n(\"entity\"<|>UGT1A9<|>ORGANIZATION<|>UGT1A9是一种代谢酶，参与达格列净的代谢)\n##\n(\"entity\"<|>UGT2B7<|>ORGANIZATION<|>UGT2B7是一种代谢酶，参与恩格列净的代谢)\n##\n(\"entity\"<|>UGT1A3<|>ORGANIZATION<|>UGT1A3是一种代谢酶，参与恩格列净的代谢)\n##\n(\"entity\"<|>UGT1A8<|>ORGANIZATION<|>UGT1A8是一种代谢酶，参与恩格列净的代谢)\n##\n(\"entity\"<|>CYP450<|>ORGANIZATION<|>CYP450是一种代谢酶家族，参与多种药物的代谢)\n##\n(\"relationship\"<|>沙格列汀<|>CYP3A4<|>沙格列汀的代谢受CYP3A4的影响<|>5)\n##\n(\"relationship\"<|>沙格列汀<|>CYP2C8<|>沙格列汀的代谢受CYP2C8的影响<|>5)\n##\n(\"relationship\"<|>西格列汀<|>P-gp<|>西格列汀是P-gp的底物<|>7)\n##\n(\"relationship\"<|>利格列汀<|>P-gp<|>利格列汀是P-gp的底物<|>7)\n##\n(\"relationship\"<|>维格列汀<|>P-gp<|>维格列汀是P-gp的底物<|>7)\n##\n(\"relationship\"<|>罗格列酮<|>CYP2C8<|>罗格列酮主要经CYP2C8代谢<|>8)\n##\n(\"relationship\"<|>吡格列酮<|>CYP2C8<|>吡格列酮主要经CYP2C8代谢<|>8)\n##\n(\"relationship\"<|>达格列净<|>UGT1A9<|>达格列净主要经UGT1A9代谢<|>8)\n##\n(\"relationship\"<|>恩格列净<|>UGT2B7<|>恩格列净经UGT2B7代谢<|>7)\n##\n(\"relationship\"<|>恩格列净<|>UGT1A3<|>恩格列净经UGT1A3代谢<|>7)\n##\n(\"relationship\"<|>恩格列净<|>UGT1A8<|>恩格列净经UGT1A8代谢<|>7)\n##\n(\"relationship\"<|>恩格列净<|>UGT1A9<|>恩格列净经UGT1A9代谢<|>7)\n##\n(\"relationship\"<|>卡格列净<|>CYP3A4<|>卡格列净仅有7%经CYP3A4代谢<|>5)\n<|COMPLETE|>"}, {"content": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "role": "user"}], "parameters": {"model": "deepseek-chat", "frequency_penalty": 0.0, "max_tokens": null, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0}}, "key": "chat_extract-continuation-0_9acba74cf4cd3ff0e674048f79e85b197f44ed4630748218f88c4df2f3f87c37_v2"}